Make incurable
disease curable
Every cancer drug of the last century aimed at one target. Tumors route
around one target. We are building the AI that steers the whole cell.

People who have died of cancer
since you opened this site
00
Three in a hundred cancer drugs that enter human trials reach approval. Two in three of those approved since 2006 have never been shown to extend life. The ones that have, extend it by a median of about two months. It is not for lack of effort. Most AI in drug discovery runs the same century-old play — one target, one drug — faster.
The problem is the idea.
High-Dimensional Medicine
Not a better
bullet – A way
to steer
A cell’s behavior, whether it divides, invades, resists treatment or dies, is set by thousands of interacting signals. Block one and the network finds another route.
Conquest’s AI watches living cells respond as dozens of drugs are changed at once, learns the rules, and designs the combination that pushes the whole cell where we want it — remodeling its behavior.
Why now
Robotic microscopes can now watch living cells respond to thousands of perturbations at once. AI can learn from what they see. Neither was true ten years ago.
A lab that learns.
A model that experiments.
Biology has no internet to train on, so we generate our own data.
Our lab generates ~1.5 million images of living cells a week. We plan to increase that rate 100x over the next 12 months.
Generating 1.5m live cell images per week
Watch
Living cells, before and after, around the clock.
Learn
Models that predict how drugs and doses combine.
Steer
Design the combination. Test it. Repeat.
Why cancer

Cancer is the hardest version of the problem: a tumor is thousands of cells, each finding its own way around treatment. Oncologists watch it happen every day. We want their knowledge shaping the questions our models learn to answer.
Lasting recovery where today there is none. A future that reaches beyond the next scan. Ordinary days, in extraordinary numbers.
Every disease was incurable once.
Work with us.
We are hiring researchers and engineers. We also want to hear from oncologists, investors and regulators.